The pancreas: when the digestive enzymes are missing

It is half past six in the morning and you are standing in front of the toilet, looking in for longer than you would like. Something is floating. It has a sheen. It does not go away with the first flush.

Yesterday was the same. The day before, after the restaurant, it was especially noticeable. You started avoiding fatty food, and somehow things improved. So it was the fat, you think.

Many people know this pattern. First comes the observation, then comes the search engine, and then comes a word you never needed before: steatorrhoea. Two clicks further on, it says pancreatic cancer.

So I am not starting with reassurance. I am starting with the organ. Because once you understand how much reserve the pancreas has, you also understand why it shows up so late and why a single laboratory value so often misleads.

The organ that takes more than you think

Do you know the feeling that a body part only exists once it hurts? With the pancreas it is even more extreme. It can shrink over years without you noticing anything at all.

It lies crosswise behind the stomach, about fifteen centimetres long, soft, inconspicuous. And it has two very different jobs in the same tissue.

One job is the familiar one: insulin and glucagon, so blood sugar. That is the endocrine part, a tiny share of the cell mass. The other job makes up more than ninety percent of the organ and is called exocrine. It consists of sending one to two litres of digestive juice into the duodenum every day.

That juice contains four things you should know about.

And now comes the idea this whole article turns on: the reserve.

This work is old and small, and in PubMed it does not even have an abstract. I still name it, because it has appeared in every guideline for fifty years. It describes an order of magnitude, not an exact threshold.

Picture a power station supplying a whole city. It has twelve turbines. Nine fail one after another, and the lights in the city stay on. Only when the tenth stops does the light flicker. From the outside, everything looked the same for ten years.

And now you know why this organ is so hard to pin down. It reports late, and it reports non specifically.

How you notice it, and why it looks unremarkable for so long

May I ask you an uncomfortable question? How long have you been looking at this without talking to anyone about it?

What stands out in the bathroom

Steatorrhoea is described fairly consistently in the literature. Large volume. Pale to clay coloured. Shiny or greasy. Harsh smelling, clearly different from usual. Often floating, often hard to flush away, sometimes with a film on the water.

The search query is usually different. It reads: why does my stool float. And the honest answer to that is unsatisfying.

Floating can be down to fat. More often it is down to trapped gas, and gas arises with any fermentation in the large intestine, pancreas problem or not. As a single feature it is not useful.

And duration is the most important word here. A single day after a very fatty dinner says nothing. A pattern over weeks says something.

The sentence that surprises most people

The widespread idea is: if you do not absorb your food, you become thin. That is often true, but far from always.

It goes further still. The disorder can exist without anything on the surface pointing to it.

And now you know why this picture is so often missed. From the outside it looks like nothing.

Red flags and where self assessment ends

If you landed here via a search engine, I know your real question. It is usually not in the search box, but it is in your head. It reads: is this cancer.

I deal with that soberly, because that is the only stance that holds.

Yes, a tumour of the pancreas is among the possible causes of exocrine insufficiency. That is exactly why the rule exists that an abnormal finding belongs in medical assessment. Assessment is how that possibility is handled. It is not proof of it.

And yes, the more common causes are others. Chronic pancreatitis, the aftermath of acute pancreatitis, surgery on the stomach or pancreas, diabetes, coeliac disease, inflammatory bowel disease. We will work through that list in order shortly.

And now the sentence that matters most to me on this topic.

I have described the broad search for causes of persistent diarrhoea in detail elsewhere, in the article on chronic diarrhoea and its overlooked causes. Here I follow only the one trail that leads to the pancreas.

And now you know where this text ends and where an examination begins.

Where it comes from: the map of causes

Many overviews list the causes alphabetically. That is tidy, but it does not tell you what is likely in your situation.

So I sort by frequency and by explanatory power. If you have one of these histories, it changes the meaning of an abnormal value considerably. That is the pre test probability, and in the next section it is the key to everything.

The most common cause in adults: chronic pancreatitis

In chronic pancreatitis, glandular tissue is lost over years and replaced by connective tissue. At the end there is often both: too little digestive enzyme and too little insulin.

The two big drivers are alcohol and smoking. I name that factually and without a moral undertone, because blame gets nobody anywhere who is already in this situation.

What else alcohol can do in the digestive tract is in the article on alcohol and the gut.

After acute pancreatitis

After surgery on the stomach, oesophagus or pancreas

Two different mechanisms are at work here, and the distinction is instructive.

After partial removal of the pancreas, tissue is simply missing. In the Liverpool cohort, in which everyone had been operated on for a malignant disease, fat uptake was impaired in 55 percent of those examined one year after the operation.

After removal of the stomach, by contrast, the pancreas is intact. The problem is timing. Food reaches the small intestine in a different rhythm, and the enzyme surge from the gland no longer arrives at the right place at the right time. This mechanism is called postprandial asynchrony.

Diabetes, and the type 3c chapter

Insulin and digestive enzymes come from the same organ. So it is hardly surprising that both functions can suffer together. What is more surprising is how rarely it is considered.

The prevalence figures vary enormously. A systematic review reports 14 to 77.5 percent for type 1 diabetes with a median of 33 percent, and 16.8 to 49.2 percent for type 2 diabetes with a median of 29 percent, against 4.4 to 18 percent in control groups. An Austrian position paper arrives at similar orders of magnitude with similarly wide ranges.

I deliberately give these figures as a range and not as a point estimate. Behind them lie very different cut-offs and very different populations. Turning that into a sentence such as "one in three people with diabetes has pancreatic insufficiency" overstretches the data.

Type 3c diabetes is the counterpart: a diabetes that arises from a disease of the pancreas itself. It is often misread as type 2, because nobody asks about the history.

Coeliac disease, when the diarrhoea persists despite a gluten free diet

Inflammatory bowel disease

How Crohn's disease and ulcerative colitis can be accompanied integratively is in the article on inflammatory bowel disease. Here only one point matters: a low elastase value during active diarrhoea often means something other in this group than it seems to mean at first glance.

The rest of the map

And now you know why the first question is not how high your value is, but what your history looks like.

The elastase value, explained honestly

You are holding a piece of paper with a number on it. Maybe 150. Maybe 87. Next to it an arrow pointing down and the note that above 200 would be normal.

Your pulse goes up. Understandably. Most texts now start either reassuring you or giving you a diagnosis. Instead I will explain what this value measures and how reliable it is.

What is being measured

Among many other enzymes, the pancreas produces one called elastase-1. This enzyme has a practical property: it survives the passage through the whole gut largely unchanged. What is released at the top arrives at the bottom.

So the amount of elastase-1 per gram of stool is an indirect mirror of what the gland releases. The test is simple, it needs a single stool sample, and that is exactly why it is the sensible first step in every guideline. Not because it is the most accurate. Because it is feasible.

What the test can and cannot do

The key: how likely was it before the test

A test only shifts probabilities. How far depends on how likely the thing was beforehand. So the same number means two different things in two different people.

The dilution effect: why watery stool pulls the value down

Now comes a point that rarely appears in patient facing texts, although it can be one of the most common explanations for an abnormal result. The value is given as an amount of enzyme per gram of stool, so as a fraction. If there is more water in the stool, the result falls. Without the gland doing anything differently.

Picture two glasses of juice. Both contain the same amount of juice. Into the second one you pour half a litre of water. Now measure the sweetness per sip. The juice has not become less, the concentration has.

Do I have to stop my enzyme capsules beforehand?

That is one of the most frequent questions, and the answer is pleasingly clear. No.

The reason is rarely supplied, although it is simple. What is measured is human elastase-1. The commercially available enzyme preparations are obtained from porcine pancreas. With the test methods in use today, which rely on antibodies specific to human elastase-1, the preparation cannot raise the value. Older methods could partly detect the porcine enzyme as well. If you are unsure which method your laboratory uses, that is a good question for your next appointment.

The AGA states explicitly that testing during ongoing enzyme replacement therapy is acceptable. And independently of that, the sentence I will write several more times in this article applies: you do not start or stop any of this yourself. Every adjustment belongs in medical hands.

And what do I do now with a 150?

The honest answer has three steps, and none of them is called treat immediately.

One last note for context: the elastase test is something entirely different from a microbiome stool test. One measures a human enzyme, the other measures bacteria. What stool tests for dysbiosis can and cannot do is in the article on stool testing and dysbiosis diagnostics.

And now you know why the same number can mean two different things in two different people.

What else can be checked when the value alone is not enough

You may be thinking: then just give me the accurate test. That question is fair, and the answer is sobering.

More accurate methods exist. They are elaborate and barely available outside specialist centres. That is why the simple test is the standard and not the best.

The 13C mixed triglyceride breath test

The 72 hour faecal fat measurement

This is the actual reference standard: for three days all stool is collected, on a defined diet with enough fat. It is informative and is almost never carried out in practice, because the effort for everyone involved is high.

Imaging: endoscopic ultrasound, MRCP, computed tomography

Here comes a distinction that can clear up a lot of confusion.

Endoscopic ultrasound looks at the gland from inside the stomach and sees early structural changes well. MRCP shows the ducts. Both answer the question of structure, not of function.

What they do not answer: how much enzyme reaches the gut.

Blood values that prove nothing

Amylase and lipase in the blood are the best known pancreatic values. They say nothing about digestive capacity.

They rise when enzymes leak from inflamed tissue into the blood, typically during acute inflammation. With a slowly shrinking gland they can be unremarkable or even low.

So if someone says your pancreas is fine because amylase and lipase are normal, that holds for the question of acute inflammation. For the question of digestive capacity, that conclusion does not carry.

What the German guideline clarifies

The European guideline, backed by seven professional societies, turns the consequence into a rule: the diagnosis of exocrine pancreatic insufficiency should rest on an overall view of symptoms, nutritional status and a function test. Not on a single value.

And now you know why there is no single perfect test and why that is not a failure but a property of the field.

Once the diagnosis is established: what the guidelines say

Up to here I have been putting on the brakes. Now I stop braking.

If exocrine pancreatic insufficiency is confirmed, then enzyme replacement is not an optional extra and not one alternative among several. It is the standard, and all six guidelines and position papers I read for this article say so in agreement.

I write that so plainly because the wish for a natural route is an obvious one. For exocrine pancreatic insufficiency I know of none that could replace enzyme replacement. What there is are sensible additions alongside it. That is a difference.

What the enzymes measurably change

A post hoc analysis of the same study found a rise of 36.0 percent with diabetes against 7.5 on placebo, and 25.2 against 12.3 percent without diabetes. The numbers are small, the direction is clear: diabetes is no reason for restraint.

A systematic review of 22 randomised studies contained exactly one direct comparison of two preparations. For protein uptake over 72 hours, no meaningful difference showed up there. What counts may be the amount and the timing rather than the brand. The author group was close to a manufacturer, and the two products compared are prescription only in the United States.

A note for Germany: pancreatin preparations are pharmacy only here in many strengths and can therefore be bought without a prescription. That does not make them something to experiment with. Without a confirmed diagnosis you may be treating the wrong problem and delaying the right work up.

The dose, and why it is almost always too low

The timing, which makes surprisingly much difference

The matter of stomach acid

Here it gets interesting, because at this point two things appear to contradict each other.

In my clinic I like to look upstream first, before I think about digestive enzymes: is there enough acid in the stomach at all? That is a clinical habit of mine and not a guideline recommendation, and the evidence for it is thin. Too little stomach acid can cause symptoms that resemble those of too little pancreatic enzyme. What matters is the order: if red flags are in the room or an assessment has been recommended, that comes first and not a self test. The details are in the article on low stomach acid and betaine HCl.

And the AGA writes: with enzyme preparations that have no enteric coating, acid suppression can be needed so that the lipase gets through the stomach. Two drug classes are meant here, the H2 blockers such as famotidine and the proton pump inhibitors such as omeprazole or pantoprazole. Both are medicines that are pharmacy only or prescription only depending on strength and pack size.

They are not harmless, and that belongs at this point. Described for long term use are, among others, poorer uptake of vitamin B12, magnesium and iron, a higher risk of intestinal infections and signals of a higher fracture risk. Headache, nausea, diarrhoea and abdominal pain occur. There are interactions, for instance with the platelet inhibitor clopidogrel and with substances whose uptake depends on stomach acid. Whether that balance works out in your case is weighed up by the prescribing practice. None of it is started or stopped on your own.

That is not a contradiction, they are two different situations. Before the diagnosis, looking upstream is worthwhile. After a confirmed diagnosis, targeted acid suppression can improve the effectiveness of certain preparations. Both are right, at different points in the course.

Only one thing matters to me here: the widespread claim that acid blockers generally improve enzyme effect is not covered by the guideline. It applies to preparations that are not enteric coated. And as with everything here: you do not start or stop any of it yourself, every adjustment belongs in medical hands. What acid blockers can otherwise do and where their downsides lie is in the article on heartburn and acid blockers.

The fat soluble vitamins, and why they belong here without exception

Vitamins A, D, E and K need fat in order to be absorbed. When fat digestion falters, that is not an additional problem. It is the same problem on a different floor.

The AGA recommends routine monitoring and supplementation of the fat soluble vitamins. And the Irish cohort from earlier supplies the brake: 19 percent had raised vitamin A levels. So supplementation belongs under monitoring and not on suspicion. The body stores most fat soluble vitamins considerably longer than the water soluble ones.

Vitamin B12 probably belongs on the list too, because pancreatic proteases are likely to be involved in an intermediate step of its uptake. On the subject of absorption problems, the article on iron deficiency in the gut fits well.

The bones, the overlooked chapter

I rarely find this point in patient facing texts. Yet it is well documented and has practical consequences.

A second meta-analysis from Boston arrives at very similar figures: osteopenia in 41.2 percent, osteoporosis in 20.9 percent, fragility fractures in 5.9 percent. So two research groups reach very similar numbers independently of one another. They draw largely on the same original studies, which makes this no true replication, but it does show that the analysis is stable.

The practical consequence is in the AGA recommendation: a bone density measurement at the start and a repeat every one to two years. The ESPEN guideline on nutrition in pancreatitis names osteoporosis and increased fracture risk explicitly as a risk to be recognised, for which preventive measures should be considered.

And blood sugar?

Here I am honest, even though it hurts the narrative arc. The Austrian position paper states explicitly that a consistent improvement in glucose metabolism through enzyme therapy has not been shown.

What is documented: better digestion, better absorption, better supply of fat soluble vitamins, lower osteoporosis risk. What is not documented: automatically better blood sugar.

Observational data on survival in pancreatic cancer are in circulation. I deliberately leave them out here. They do not come from randomised trials, they allow no statement about cause and effect, and a text for patients is not the place where a cancer prognosis is tied to a preparation. What counts for you in that situation is decided by your oncology team.

And now you know why I am plainer about the treatment than about the diagnosis, and where the limits lie here too.

Avoiding fat is, by guideline, the wrong answer

I bet you have already done it. Almost everyone does.

The stool turns fatty, so you eat less fat. Butter gone, oil sparingly, cheese rarely. And the stool does indeed become less remarkable. That is the most intuitive reaction of all, and by the data the wrong direction.

The AGA advises explicitly against very low fat diets and recommends low to moderate fat instead, spread across more frequent, smaller meals, combined with enough enzyme.

And a detail from the licensing trial tells the same story: the study was deliberately run on a diet of at least 100 grams of fat per day. Nobody wanted to know how little fat someone can tolerate. They wanted to know whether enough enzyme can handle plenty of fat too.

The two levers that really are yours

Alcohol. It is one of the two big drivers of chronic pancreatitis. I say that without a moralising finger, because moralising improves nothing here. I say it because it is the data. And I add: if alcohol no longer feels like a free decision, that is not a question of character but a health topic like any other. General practices, addiction counselling services and the free advice offered by the Bundeszentrale für gesundheitliche Aufklärung exist for that. More on this is in the article on alcohol and the gut.

Smoking. The relative risk was 2.8 in current smokers and 2.5 after adjusting for alcohol. In former smokers it fell to 1.4. That number is the invitation.

And what about the preparations on the shelf?

This question always comes at this point, and it has an address of its own. Which enzyme preparations exist, what plant enzymes can do and when a preparation makes sense at all is described in detail in the article on digestive enzymes and when they make sense. Here it is about the organ and the diagnosis, not about the shelf.

One distinction does belong here, though, because it is so often confused. Bile emulsifies, the pancreas splits. Bile acids break fat into small droplets so that lipase can attack it at all. If bile is missing, the result looks similar to steatorrhoea, but the cause lies one floor higher. What bile, bile acids and TUDCA have to do with it is in the article on bile.

And now you know why the most obvious step with steatorrhoea can backfire.

When the enzymes are not enough: four questions in order

There is a moment I often see in the consulting room. Someone has the diagnosis, has been taking a preparation for weeks, and the symptoms are still there. The disappointment is large, and the next thought is almost always: so this does not work.

That is the point at which many people quietly drop the preparation, and exactly the wrong moment for it. Four questions are worth asking first, in this order.

How small intestinal bacterial overgrowth is assessed and treated is in the article on SIBO in the small intestine. Why it comes back so often and what motility has to do with it is in the article on SIBO relapse.

The fourth question: what else it could be

This distinction stands deliberately at the end, because at the beginning it overwhelms.

A good next step

What stands here deliberately is not a protocol and not a dose, but an order of questions that makes a conversation better.

And now you know why "it does not work" is almost never the end of the story, but the beginning of the next question.

Frequent questions about the pancreas and elastase

These are the questions I am asked most often on this topic. If yours is among them, you will find the short answer here and the long one above in the text.

Where the pancreas connects to the rest of the digestive tract

This organ never works alone. Above it sits the stomach with its acid, next to it the bile duct opens, below it lies the small intestine. Whoever looks only at one value misses the interplay.